[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100116699":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":10,"locations":23,"responsibleParty":132,"collaborators":10,"id":134,"slug":135,"hasResults":136,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":136,"sex":142,"minAge":143,"maxAge":10,"enrollmentInfo":144,"targetDuration":10,"studyType":147,"phases":10,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":156,"whyStopped":10,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Aromatase inhibitors",null,"Early stage postmenopausal breast cancer patients under tamoxifen treatment who are switching to aromatase inhibitor treatment",[13],"Other: Aromatase inhibitors",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"OTHER","non-interventional study",[9],[20],{"name":21,"affiliation":5,"role":22},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[24,35,43,48,52,59,66,73,80,87,95,99,107,111,118,125],{"facility":25,"status":10,"city":26,"state":10,"zip":27,"country":28,"countryCode":10,"cosmosGeoPoint":29,"geoPoint":34,"contacts":10},"Pfizer Investigational Site","Adana","01330","Turkey (Türkiye)",{"type":30,"coordinates":31},"Point",[32,33],35.32531,36.98615,{"lat":33,"lon":32},{"facility":25,"status":10,"city":36,"state":10,"zip":37,"country":28,"countryCode":10,"cosmosGeoPoint":38,"geoPoint":42,"contacts":10},"Ankara","06100",{"type":30,"coordinates":39},[40,41],32.85427,39.91987,{"lat":41,"lon":40},{"facility":25,"status":10,"city":36,"state":10,"zip":44,"country":28,"countryCode":10,"cosmosGeoPoint":45,"geoPoint":47,"contacts":10},"06590",{"type":30,"coordinates":46},[40,41],{"lat":41,"lon":40},{"facility":25,"status":10,"city":36,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":49,"geoPoint":51,"contacts":10},{"type":30,"coordinates":50},[40,41],{"lat":41,"lon":40},{"facility":25,"status":10,"city":53,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":54,"geoPoint":58,"contacts":10},"Bursa",{"type":30,"coordinates":55},[56,57],29.06013,40.19559,{"lat":57,"lon":56},{"facility":25,"status":10,"city":60,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":61,"geoPoint":65,"contacts":10},"Denizli",{"type":30,"coordinates":62},[63,64],29.0875,37.77417,{"lat":64,"lon":63},{"facility":25,"status":10,"city":67,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":68,"geoPoint":72,"contacts":10},"Edirne",{"type":30,"coordinates":69},[70,71],26.55597,41.67719,{"lat":71,"lon":70},{"facility":25,"status":10,"city":74,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":75,"geoPoint":79,"contacts":10},"Erzurum",{"type":30,"coordinates":76},[77,78],41.27694,39.90861,{"lat":78,"lon":77},{"facility":25,"status":10,"city":81,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":82,"geoPoint":86,"contacts":10},"Gaziantep",{"type":30,"coordinates":83},[84,85],37.3825,37.05944,{"lat":85,"lon":84},{"facility":25,"status":10,"city":88,"state":10,"zip":89,"country":28,"countryCode":10,"cosmosGeoPoint":90,"geoPoint":94,"contacts":10},"Istanbul","34303",{"type":30,"coordinates":91},[92,93],28.94966,41.01384,{"lat":93,"lon":92},{"facility":25,"status":10,"city":88,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":96,"geoPoint":98,"contacts":10},{"type":30,"coordinates":97},[92,93],{"lat":93,"lon":92},{"facility":25,"status":10,"city":100,"state":10,"zip":101,"country":28,"countryCode":10,"cosmosGeoPoint":102,"geoPoint":106,"contacts":10},"Izmir","35340",{"type":30,"coordinates":103},[104,105],27.13838,38.41273,{"lat":105,"lon":104},{"facility":25,"status":10,"city":100,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":108,"geoPoint":110,"contacts":10},{"type":30,"coordinates":109},[104,105],{"lat":105,"lon":104},{"facility":25,"status":10,"city":112,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":113,"geoPoint":117,"contacts":10},"Kocaeli",{"type":30,"coordinates":114},[115,116],27.51145,39.62497,{"lat":116,"lon":115},{"facility":25,"status":10,"city":119,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":120,"geoPoint":124,"contacts":10},"Malatya",{"type":30,"coordinates":121},[122,123],38.31667,38.35018,{"lat":123,"lon":122},{"facility":25,"status":10,"city":126,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":127,"geoPoint":131,"contacts":10},"Trabzon",{"type":30,"coordinates":128},[129,130],39.72694,41.005,{"lat":130,"lon":129},{"type":133,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100116699","research-of-quality-of-life-and-safety-outcomes-of-postmenopausal-breast-cancer-patients-switching-from-tamoxifen-therapy-to-aromatase-inhibitor-therapy-100116699",false,"NCT00784888","Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy","A Non-Interventional Study Evaluating The Effects Of Aromatase Inhibitor Treatment After 2-3 Years Tamoxifen - As Adjuvant Endocrine Therapy - On Quality Of Life And Safety In Endocrine Responsive Early Stage Postmenopausal Breast Cancer Patients","TAMARA","Inclusion Criteria:\n\nPatients with endocrine responsive early stage postmenopausal breast cancer. Patients who received tamoxifen for 2-3 years as adjuvant endocrine therapy. Patients who were approved to switch to aromatase inhibitor treatment during the patient recruitment period.\n\nPatients who were informed about the study and accepted to participate.\n\nExclusion Criteria:\n\nPatients having a psychological disorder which will prevent their understanding of questionnaires used for evaluation of quality of life and \u002F or patients who are illiterate.","FEMALE","40 Years",{"count":145,"type":146},344,"ACTUAL","OBSERVATIONAL","The purpose of this study is to follow safety and quality of life outcomes on patients switching from tamoxifen therapy to aromatase inhibitor therapy.",[150],"Breast Neoplasms",[152,153,154,155],"aromatase inhibitor","quality of life","safety","postmenopausal breast cancer","COMPLETED","2012-03-14",{"date":159,"type":160},"2012-03-15","ESTIMATED",{"date":162,"type":10},"2008-06",{"date":164,"type":146},"2011-12",{"name":5,"class":6},16]